555,894 Shares in Prestige Consumer Healthcare Inc. $PBH Purchased by Bank of America Corp DE

Key Points

• Bank of America acquired 555,894 shares of Prestige Consumer Healthcare in the second quarter, valued at approximately $26.3 million and representing a 1.17% stake. Institutional investors collectively own 99.95% of PBH.
• Prestige Consumer Healthcare exceeded quarterly expectations, reporting $0.98 EPS versus the $0.89 consensus and revenue of $265.71 million, up 6.5% year over year.
• PBH shares opened at $45.99, well below their 52-week high of $71.07. Analysts maintain a consensus “Hold” rating with a target price of $67.67.

Bank of America Corp DE purchased a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 555,894 shares of the company's stock, valued at approximately $26,277,000. Bank of America Corp DE owned about 1.17% of Prestige Consumer Healthcare at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc raised its stake in shares of Prestige Consumer Healthcare by 47.9% during the 2nd quarter. Versant Capital Management Inc now owns 726 shares of the company's stock worth $34,000 after acquiring an additional 235 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company's stock valued at $35,000 after acquiring an additional 236 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Prestige Consumer Healthcare by 19.4% in the first quarter. EverSource Wealth Advisors LLC now owns 1,531 shares of the company's stock worth $91,000 after purchasing an additional 249 shares during the last quarter. ProShare Advisors LLC grew its holdings in Prestige Consumer Healthcare by 3.0% in the fourth quarter. ProShare Advisors LLC now owns 9,597 shares of the company's stock worth $592,000 after purchasing an additional 279 shares during the last quarter. Finally, Illinois Municipal Retirement Fund increased its position in shares of Prestige Consumer Healthcare by 1.1% during the first quarter. Illinois Municipal Retirement Fund now owns 26,114 shares of the company's stock worth $1,548,000 after purchasing an additional 281 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $45.99 on Thursday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. The company's fifty day moving average price is $50.48 and its 200-day moving average price is $52.11. Prestige Consumer Healthcare Inc. has a 1-year low of $42.62 and a 1-year high of $71.07. The firm has a market capitalization of $2.18 billion, a PE ratio of 12.88, a price-to-earnings-growth ratio of 1.50 and a beta of 0.33.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $0.09. The company had revenue of $265.71 million during the quarter, compared to analyst estimates of $253.02 million. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The firm's quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter last year, the business posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current year.

Analyst Ratings Changes

PBH has been the subject of several analyst reports. Zacks Research upgraded Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a report on Monday, August 10th. Weiss Ratings downgraded Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, June 25th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $67.67.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc NYSE: PBH develops, markets and distributes over-the-counter health care products and household consumer products. Its portfolio includes branded treatments for eye care, gastrointestinal health, women's health, oral care, respiratory conditions, pain relief and skin care, along with products for lice treatment and motion sickness.

The company's brands include Clear Eyes, Dramamine, Monistat, Summer's Eve, Compound W, Chloraseptic, Luden's, BC, Goody's, Nix and Hydralyte, among others.

Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.